A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in ...
A Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in bone tissue, offering a ...
A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in bone tissue, offering a ...
Zydus introduces biosimilar denosumab 120 mg SC – protecting bone health in cancer patients: Our Bureau, Mumbai Wednesday, December 10, 2025, 13:30 Hrs [IST] Zydus Lifesciences ...
Capital Market on MSN
Zydus Lifesciences gains after launching Denosumab Biosimilar
Zydus Lifesciences rose 1.61% to Rs 934.75 after the company announced the launch of Zyrifa, a biosimilar of Denosumab 120 mg, aimed at improving access to advanced bone-health treatments.
Tribune Content Agency on MSN
How is metastatic prostate cancer detected and treated in men over 70?
National guidelines on prostate cancer screening with the PSA test are set by the US Preventive Services Task Force. Marc B. Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical ...
Tribune Content Agency on MSN
Can men hold off on treating recurring prostate cancer?
What happens if PSA levels start rising after surgery or radiation for prostate cancer? Up to a third of men treated for the disease will eventually confront this problem. If there's no accompanying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback